









Markets
/
Stocks
/
nasdaq-cldi
/

Calidi Biotherapeutics Inc

CLDI

1.540USD

-0.040-2.53%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

4.43MMarket Cap

LossP/E TTM



Calidi Biotherapeutics Inc

1.540

-0.040-2.53%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy.

Score

Industry at a Glance

Industry Ranking

201 / 506

Overall Ranking

325 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

10.000

Target Price

+4247.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.

Overvalued

The company’s latest PE is 0.06, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 629.19K shares, increasing 33.22% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.93.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.19, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.19

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.40, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.06, which is -84.78% below the recent high of 0.01 and 695.58% above the recent low of -0.36.

Score

Industry at a Glance

Previous score

3.40

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 201/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Calidi Biotherapeutics Inc is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

10.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

10.000

Target Price

+4247.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Calidi Biotherapeutics Inc

CLDI

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

There is no price momentum score for this company; the Biotechnology & Medical Research industry's average is 6.58.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.009

Sell

RSI(14)

41.520

Neutral

STOCH(KDJ)(9,3,3)

16.539

Sell

ATR(14)

0.076

Low Volatility

CCI(14)

-146.406

Sell

Williams %R

86.364

Oversold

TRIX(12,20)

-2.399

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.588

Sell

MA10

1.610

Sell

MA20

1.627

Sell

MA50

2.095

Sell

MA100

1.237

Buy

MA200

1.127

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Leftwich (Scott)

259.54K

Schoeneck (James A)

114.13K

Armistice Capital LLC

3.32M

Jamir Trust

608.38K

BMO Nesbitt Burns Inc.

489.80K

+3818.40%

Kessler (Judd S)

372.98K

The Vanguard Group, Inc.

Star Investors

353.38K

+475.78%

AJC Capital LLC

281.51K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.95, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.